MODEL VERDICT
OPKO Health, Inc. (OPK)
Relative Valuation•Peer multiples, Monte Carlo simulation & quality-adjusted fair value
Popular:
Composite score derived from valuation, quality, and risk factors
Quantitative model thresholds · For educational and research purposes only
Each row records the model's monthly assessment. High Conviction = the model detected notable undervaluation vs peers. Neutral = no notable divergence was found. The return column shows the actual price change over 90 days for reference. This is a quantitative observation log — not investment advice.
| Date | Assessment | Score | Price | Status | 90d Fwd Return |
|---|---|---|---|---|---|
| May 1, 2026 | MODERATE | 0.62 | $1.10 | CURRENT | — |
| Apr 24, 2026 | MODERATE | 0.62 | $1.23 | CURRENT | — |
| Apr 17, 2026 | MODERATE | 0.62 | $1.24 | CURRENT | — |
| Apr 16, 2026 | MODERATE | 0.62 | $1.18 | CURRENT | — |
| Apr 10, 2026 | MODERATE | 0.62 | $1.16 | CURRENT | — |
Historical model observations for research purposes only. Past quantitative patterns do not predict future results. Not a recommendation to buy, sell, or hold any security.
| Methodology | Fair Value | vs Current | Weight | Quality | Status |
|---|---|---|---|---|---|
| EV To Revenue 8 industry peers | $2.33 | +111.8% | 4% | B | Data |
| Price / Sales 8 industry peers | $2.15 | +95.5% | 3% | B | Model Driven |
| Weighted Output Blended model output | $1.78 | +61.8% | 100% | 58 | SIGNIFICANTLY UNDERVALUED |
Cross-sectional regression predicting expected multiples based on growth, margins, ROIC, and beta.
| Multiple | Avg | Median | Min | Max | Std |
|---|---|---|---|---|---|
| EV/EBIT | 245.08 | 38.98 | 29.45 | 666.80 | 365.25 |
| P/FFO | 36.23 | 22.70 | 21.83 | 64.18 | 24.20 |
| P/TBV | 19.15 | 12.34 | 3.61 | 41.50 | 19.84 |
| P/AFFO | 90.60 | 51.16 | 30.76 | 189.88 | 86.58 |
| P/B Ratio | 0.97 | 0.76 | 0.54 | 1.85 | 0.50 |
| P/S Ratio | 1.39 | 1.43 | 0.90 | 1.76 | 0.35 |
Based on our peer multiples analysis with 5 valuation metrics, the model estimates OPK's fair value at $1.78 vs the current price of $1.10, implying +61.8% upside potential. Model verdict: Significantly Undervalued. Confidence: 58/100. This is a quantitative estimate, not a recommendation.
The blended fair value of $1.78 is calculated using four lenses: industry median multiples (40%), historical multiples (30%), forward estimates (20%), and quality-adjusted multiples (10%). Monte Carlo simulation (10,000 iterations) gives a range of $0.72 (P10) to $3.70 (P90), with a median of $2.06.
OPK's current P/E of -3.7x compares to the industry median of 23.6x (4 peers in the group). This represents a -115.5% discount to the industry. The historical average P/E is N/Ax over 0 years. Signal: Deep Discount.
13 analysts cover OPK with a consensus rating of Buy. The consensus price target is $2.87 (range: $1.60 — $4.00), implying +160.9% upside from the current price. Grade breakdown: Strong Buy (0), Buy (8), Hold (4), Sell (1), Strong Sell (0).
The model confidence score is 58/100, based on: data completeness (6), peer quality (25), historical depth (20), earnings stability (5), and model agreement (2). Cyclicality penalty: -0 points. The model shows moderate agreement across inputs.
The model flags several key risks: (1) Macro/regulatory risks are not captured in this model but remain material.
Peak earnings risk data is not available for OPK.
No. This dashboard is a quantitative research tool for educational and informational purposes only. It is not investment advice, a solicitation, or a recommendation to buy, sell, or hold any security. The operator of this platform is not a registered investment advisor (RIA), broker-dealer, or financial planner. All model outputs, fair value estimates, signals, and scenarios are the result of automated quantitative computations and should not be construed as professional financial guidance. You should consult a qualified, licensed financial advisor before making any investment decisions. Past model performance is not indicative of future results.